Photo of Elizabeth Anne Mullen,  MD

Elizabeth Anne Mullen, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-1938


elizabeth_mullen@dfci.harvard.edu

Elizabeth Anne Mullen, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Pediatrics, Harvard Medical School
  • Staff Physician, Pediatric Oncology, Dana-Farber Cancer Institute
  • MD, Medicine, Boston Children's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

As an academic clinician, I have developed expertise in Pediatric Renal Tumors, have regional and national leadership roles, and a strong international reputation in clinical expertise. I am the Program Leader and Institutional Disease Expert for Renal Tumors at DFCI/BCH. In this capacity, I am involved in the care and treatment plans for all patients with Renal Tumors seen at our program. I am a member of the COG Renal Tumors Steering Committee and am Chair of the Renal Tumors Biology and Classification Study, as well as the Vice-Chair for the protocol for Treatment of Very Low Risk and Standard Risk Wilms Tumor. I have responsibility for real time central review of central radiology, pathology and surgical reports of all renal tumor patients nationally (over 600 patients a year) and assignment of appropriate risk stratification to allow enrollment on appropriate therapeutic studies, a large national study which has enrolled almost 6000 patients since 2006. My interest in the improvement of outcomes in pediatric renal tumor patients has lead a study of urine proteomics to identify urinary markers of high risk renal disease. I currently chair the COG working group for the development of the next therapeutic study for patients with Favorable Histology Wilms Tumor, which will aim to incorporate additional biologic markers in risk stratification.

Publications

Powered by Harvard Catalyst
  • Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, Rohan SM, Cost NG, Khanna G, Mullen EA, Dome JS, Fernandez CV, Perlman EJ. The classification of pediatric and young adult renal cell carcinomas registered on the Children's Oncology Group (COG) protocol AREN03B2 after focused genetic testing. Cancer 2018. PubMed
  • Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, Mullen EA, Geller JI, Kalapurakal JA, Paulino AC, Perlman EJ, Ehrlich PF, Malogolowkin M, Gastier-Foster JM, Wagner E, Grundy PE, Fernandez CV, Dome JS. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol 2018; 36:1564-1570. PubMed
  • Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, Khanna G, Paulino AC, Hamilton TE, Gow KW, Tochner Z, Hoffer FA, Withycombe JS, Shamberger RC, Kim Y, Geller JI, Anderson JR, Grundy PE, Dome JS. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol 2018. PubMed
  • Ehrlich P, Chi YY, Chintagumpala MM, Hoffer FA, Perlman EJ, Kalapurakal JA, Warwick A, Shamberger RC, Khanna G, Hamilton TE, Gow KW, Paulino AC, Gratias EJ, Mullen EA, Geller JI, Grundy PE, Fernandez CV, Ritchey ML, Dome JS. Results of the First Prospective Multi-institutional Treatment Study in Children With Bilateral Wilms Tumor (AREN0534): A Report From the Children's Oncology Group. Ann Surg 2017; 266:470-478. PubMed
  • Sandberg JK, Mullen EA, Cajaiba MM, Smith EA, Servaes S, Perlman EJ, Geller JI, Ehrlich PF, Cost NG, Dome JS, Fernandez CV, Khanna G. Imaging of renal medullary carcinoma in children and young adults: a report from the Children's Oncology Group. Pediatr Radiol 2017. PubMed
  • Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract 2017; 13:414-421. PubMed
  • Yi JS, Kamihara J, Kesselheim JC, Davies K, van Hoff J, Silverman LB, Mullen EA. Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan. Pediatr Blood Cancer 2016. PubMed
  • Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, Grundy P, Mullen EA, Geller JI, Fernandez CV, Perlman EJ. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol 2016; 34:3189-94. PubMed
  • Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, Ferrer FA, Barnhart DC, Ehrlich PF, Khanna G, Kalapurakal JA, Bocking T, Huff V, Tian J, Geller JI, Grundy PE, Anderson JR, Dome JS, Shamberger RC. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg 2016. PubMed
  • Cajaiba MM, Khanna G, Smith EA, Gellert L, Chi YY, Mullen EA, Hill DA, Geller JI, Dome JS, Perlman EJ. Pediatric cystic nephromas: distinctive features and frequent DICER1 mutations. Hum Pathol 2016; 48:81-7. PubMed
  • Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van den Heuvel-Eibrink M, Pritchard-Jones K. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. J Clin Oncol 2015; 33:2999-3007. PubMed
  • Geller JI, Ehrlich PF, Cost NG, Khanna G, Mullen EA, Gratias EJ, Naranjo A, Dome JS, Perlman EJ. Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2. Cancer 2015; 121:2457-64. PubMed
  • Servaes S, Khanna G, Naranjo A, Geller JI, Ehrlich PF, Gow KW, Perlman EJ, Dome JS, Gratias E, Mullen EA. Comparison of diagnostic performance of CT and MRI for abdominal staging of pediatric renal tumors: a report from the Children's Oncology Group. Pediatr Radiol 2015; 45:166-72. PubMed
Hide